Seismic Therapeutic Highlights Preclinical Data of S-1117 for the Treatment of Autoimmune Disorders at AAN 2024
Shots:
- Seismic presented the preclinical data of S-1117, Fc-fused pan-IgG protease, at AAN 2024 highlighting in vitro & in vivo results demonstrating its differentiated therapeutic potential
- The in vitro studies showed S-1117’s ability to cleave soluble IgG & the memory B cells’ antigen BCR, immune complex degradation in tissues & circulation as well as decreased IgG effector functions incl. antibody-dependent cytotoxicity (ADCC) & complement-dependent cytotoxicity (CDC) of PBMCs
- The in vivo studies in the murine PK/PD model depicted decreased IgG levels while the murine nephritis model demonstrated a reduction in complement & immune complex deposition along with lowered proteinuria, blood urea nitrogen & renal pathology
Ref: Seismic Therapeutic | Image: Seismic Therapeutic
Related News:- Selexis Signs a Service Agreement with NexImmune to Advance Multiple Immunotherapies for Rare Cancers and Autoimmune Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
